Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPACET 100 vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Management of mild to moderate pain,Fever reduction,Off-label: Treatment of osteoarthritis pain (as acetaminophen)
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
The terminal elimination half-life of acetaminophen after propacetamol administration is approximately 2–3 hours in adults with normal hepatic function. This half-life may be prolonged in patients with hepatic impairment or overdose.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Rapidly hydrolyzed by plasma esterases to acetaminophen; acetaminophen is primarily metabolized by glucuronidation and sulfation, with a minor pathway via CYP2E1 to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Propacet 100 (propacetamol) is a prodrug of acetaminophen. Renal elimination accounts for >90% of the administered dose, with approximately 85% as acetaminophen glucuronide and sulfate conjugates, and about 5% as unchanged acetaminophen. Biliary/fecal elimination is minimal (<5%).
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Acetaminophen is minimally bound to plasma proteins, with protein binding of approximately 10–25% at therapeutic concentrations. It binds primarily to albumin.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
The volume of distribution (Vd) of acetaminophen is approximately 0.9–1.0 L/kg, indicating distribution into total body water. This reflects its hydrophilic nature and widespread tissue penetration.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Propacetamol is administered intravenously; thus, bioavailability is 100%. After hydrolysis to acetaminophen, the bioavailability of active acetaminophen is essentially complete.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
GFR 30-50 m L/min: extend interval to every 8 hours; GFR <30 m L/min: extend interval to every 12 hours; hemodialysis: dose post-dialysis.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use alternative analgesic.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
10-15 mg/kg/dose propacetamol equivalent every 6 hours; maximum 60 mg/kg/day; do not exceed adult dose.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Initiate at lower end of dosing range (100 mg every 6 hours); maximum 800 mg/day; monitor renal and hepatic function.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
No FDA black box warning exists for propacetamol specifically; however, acetaminophen (active metabolite) carries a risk of severe liver injury in cases of overdose, particularly with chronic alcohol use or hepatic impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Hepatotoxicity risk with overdose or chronic alcohol use; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) reported rarely; use with caution in hepatic impairment, alcohol use disorder, or malnutrition.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
History of hypersensitivity to acetaminophen or propacetamol; severe hepatic impairment; use of MAOIs (potential interaction).
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
No specific food interactions; however, maintain adequate caloric intake to support glutathione synthesis. Avoid alcohol as it may increase hepatotoxicity risk.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Second and third trimesters: No known fetal toxicity at therapeutic doses; overdose may cause hepatic necrosis in mother and potentially fetus.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Paracetamol is excreted into breast milk in trace amounts; milk-to-plasma ratio (M/P) is approximately 0.1-0.2. At maternal therapeutic doses, infant exposure is less than 2% of maternal weight-adjusted dose, considered compatible with breastfeeding.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Pharmacokinetic changes in pregnancy include increased clearance and volume of distribution of paracetamol, but no dose adjustment is required for Propacet 100; standard adult doses (500-1000 mg every 4-6 hours, max 4 g/day) are safe and effective.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Propacet 100 (propacetamol, a prodrug of acetaminophen) is administered intravenously; ensure patency of IV line to prevent extravasation, which can cause injection site reactions. Contraindicated in severe hepatic impairment (Child-Pugh C) and in patients with glutathione depletion (e.g., malnutrition, sepsis). Monitor liver function tests during prolonged use. Use with caution in patients with asthma, as sulfite in formulation may trigger bronchospasm.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Propacet 100 is given intravenously for pain or fever; you must receive it in a healthcare setting.,Report any signs of allergic reaction such as rash, itching, swelling, or trouble breathing immediately.,This medication is a prodrug of acetaminophen; do not take additional acetaminophen-containing products while on this therapy.,Avoid alcohol during treatment to reduce risk of liver damage.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPACET 100 vs ANEXSIA 7.5/650, answered by our medical review team.
PROPACET 100 is a Opioid analgesic combination that works by Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPACET 100 and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPACET 100 is: 1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPACET 100 and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPACET 100 is classified as Category C. Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Seco. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.